T. Rowe Price Investment Management’s Verve Therapeutics VERV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-2,491,949
| Closed | -$11.4M | – | 739 |
|
|
2025
Q1 | $11.4M | Buy |
2,491,949
+139,350
| +6% | +$637K | 0.01% | 556 |
|
|
2024
Q4 | $13.3M | Sell |
2,352,599
-72,474
| -3% | -$409K | 0.01% | 542 |
|
|
2024
Q3 | $11.7M | Sell |
2,425,073
-2,103,639
| -46% | -$10.2M | 0.01% | 545 |
|
|
2024
Q2 | $22.1M | Sell |
4,528,712
-47,712
| -1% | -$233K | 0.01% | 494 |
|
|
2024
Q1 | $60.8M | Buy |
4,576,424
+1,402,072
| +44% | +$18.6M | 0.04% | 361 |
|
|
2023
Q4 | $44.3M | Buy |
3,174,352
+1,069,054
| +51% | +$14.9M | 0.03% | 400 |
|
|
2023
Q3 | $27.9M | Buy |
2,105,298
+3,937
| +0.2% | +$52.2K | 0.02% | 445 |
|
|
2023
Q2 | $39.4M | Buy |
2,101,361
+95,234
| +5% | +$1.79M | 0.03% | 404 |
|
|
2023
Q1 | $28.9M | Buy |
2,006,127
+206,477
| +11% | +$2.98M | 0.02% | 432 |
|
|
2022
Q4 | $34.8M | Buy |
1,799,650
+544,834
| +43% | +$10.5M | 0.03% | 400 |
|
|
2022
Q3 | $43.1M | Buy |
+1,254,816
| New | +$43.1M | 0.03% | 365 |
|